Top

Published in:

19-06-2023 | Metformin | Review

The potential effect of metformin on fibroblast growth factor 21 in type 2 diabetes mellitus (T2DM)

Authors: Hayder M. Al-kuraishy, Ali I. Al-Gareeb, Hebatallah M. Saad, Gaber El-Saber Batiha

Published in: Inflammopharmacology | Issue 4/2023

Abstract

Fibroblast growth factor 21 (FGF21) is a peptide hormone mainly synthesized and released from the liver. FGF21 acts on FGF21 receptors (FGFRs) and β-Klotho, which is a transmembrane co-receptor. In type 2 diabetes mellitus (T2DM), inflammatory disorders stimulate the release of FGF21 to overcome insulin resistance (IR). FGF21 improves insulin sensitivity and glucose homeostasis. Metformin which is used in the management of T2DM may increase FGF21 expression. Accordingly, the objective of this review was to clarify the metformin effect on FGF21 in T2DM. FGF21 level and expression of FGF2Rs are dysregulated in T2DM due to the development of FGF21 resistance. Metformin stimulates the hepatic expression of FGF21/FGF2Rs by different signaling pathways. Besides, metformin improves the expression of β-Klotho which improves FGF21 sensitivity. In conclusion, metformin advances FGF21 signaling and decreases FGF21 resistance in T2DM, and this might be an innovative mechanism for metformin in the enhancement of glucose homeostasis and metabolic disorders in T2DM patients.

Aatsinki SM, Buler M, Salomäki H, Koulu M, Pavek P, Hakkola J (2014) Metformin induces PGC-1α expression and selectively affects hepatic PGC-1α functions. Br J Pharmacol 171:2351–2363PubMedPubMedCentral

Adela R, Banerjee SK (2015) GDF-15 as a target and biomarker for diabetes and cardiovascular diseases: a translational prospective. J Diabet Res 2015:1–4

Al-Kuraishy HM, Al-Gareeb AI, Waheed HJ, Al-Maiahy TJ (2018) Differential effect of metformin and/or glyburide on apelin serum levels in patients with type 2 diabetes mellitus: concepts and clinical practice. J Adv Pharm Technol Res 9:80PubMedPubMedCentral

Al-Kuraishy HM, Al-Gareeb AI, Alblihed M, Cruz-Martins N, Batiha GE (2021) COVID-19 and risk of acute ischemic stroke and acute lung injury in patients with type II diabetes mellitus: the anti-inflammatory role of metformin. Front Med (lausanne) 8:644295PubMed

Al-kuraishy HM, Al-Gareeb AI, Alexiou A, Papadakis M, Nadwa EH, Albogami SM, Alorabi M, Saad HM, Batiha GE-S (2022) Metformin and growth differentiation factor 15 (GDF15) in type 2 diabetes mellitus: a hidden treasure. J Diabet 14:806–814

Al-Kuraishy HM, Al-Gareeb AI, Saad HM, Batiha GE-S (2023) Long-term use of metformin and Alzheimer’s disease: beneficial or detrimental effects. Inflammopharmacology. https://doi.org/10.1007/s10787-023-01163-7CrossRefPubMedPubMedCentral

Al-kuraishy HM, Al-Gareeb AI, Saad HM, Batiha GE-S (2023) Long-term use of metformin and Alzheimer’s disease: beneficial or detrimental effects. Inflammopharmacology 31(3):1107–1115PubMed

Arafat A, Kaczmarek P, Skrzypski M, Pruszyńska-Oszmalek E, Kołodziejski P, Szczepankiewicz D, Sassek M, Wojciechowicz T, Wiedenmann B, Pfeiffer A (2013) Glucagon increases circulating fibroblast growth factor 21 independently of endogenous insulin levels: a novel mechanism of glucagon-stimulated lipolysis? Diabetologia 56:588–597PubMed

Archer A, Venteclef N, Mode A, Pedrelli M, Gabbi C, Clément K, Parini P, Gustafsson J-Å, Korach-André M (2012) Fasting-induced FGF21 is repressed by LXR activation via recruitment of an HDAC3 corepressor complex in mice. Mol Endocrinol 26:1980–1990PubMedPubMedCentral

Arner P, Pettersson A, Mitchell PJ, Dunbar JD, Kharitonenkov A, Rydén M (2008) FGF21 attenuates lipolysis in human adipocytes–a possible link to improved insulin sensitivity. FEBS Lett 582:1725–1730PubMed

Babalghith AO, Al-kuraishy HM, Al-Gareeb AI, De Waard M, Sabatier J-M, Saad HM, Batiha GE-S (2022) The potential role of growth differentiation factor 15 in COVID-19: a corollary subjective effect or not? Diagnostics 12:2051PubMedPubMedCentral

Bahne E, Hansen M, Brønden A, Sonne DP, Vilsbøll T, Knop FK (2016) Involvement of glucagon-like peptide-1 in the glucose-lowering effect of metformin. Diabet Obes Metab 18:955–961

Bai F, Liu Y, Tu T, Li B, Xiao Y, Ma Y, Qin F, Xie J, Zhou S, Liu Q (2019) Metformin regulates lipid metabolism in a canine model of atrial fibrillation through AMPK/PPAR-α/VLCAD pathway. Lipids Health Dis 18:1–9

Barb D, Bril F, Kalavalapalli S, Cusi K (2019) Plasma fibroblast growth factor 21 is associated with severity of nonalcoholic steatohepatitis in patients with obesity and type 2 diabetes. J Clin Endocrinol Metab 104:3327–3336PubMedPubMedCentral

Campderrós L, Moure R, Cairó M, Gavaldà-Navarro A, Quesada-López T, Cereijo R, Giralt M, Villarroya J, Villarroya F (2019) Brown adipocytes secrete GDF15 in response to thermogenic activation. Obesity 27:1606–1616PubMed

Chau MD, Gao J, Yang Q, Wu Z, Gromada J (2010) Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK–SIRT1–PGC-1α pathway. Proc Natl Acad Sci 107:12553–12558PubMedPubMedCentral

Chavez AO, Molina-Carrion M, Abdul-Ghani MA, Folli F, DeFronzo RA, Tripathy D (2009) Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabet Care 32:1542–1546

Chen C, Cheung BM, Tso AW, Wang Y, Law LS, Ong KL, Wat NM, Xu A, Lam KS (2011) High plasma level of fibroblast growth factor 21 is an Independent predictor of type 2 diabetes: a 5.4-year population-based prospective study in Chinese subjects. Diabetes Care 34:2113–2115PubMedPubMedCentral

Cho K, Chung JY, Cho SK, Shin H-W, Jang I-J, Park J-W, Yu K-S, Cho J-Y (2015) Antihyperglycemic mechanism of metformin occurs via the AMPK/LXRα/POMC pathway. Sci Rep 5:8145PubMedPubMedCentral

Christodoulides C, Dyson P, Sprecher D, Tsintzas K, Karpe F (2009) Circulating fibroblast growth factor 21 is induced by peroxisome proliferator-activated receptor agonists but not ketosis in man. J Clin Endocrinol Metab 94:3594–3601PubMed

Cuevas-Ramos D, Almeda-Valdes P, Gómez-Pérez FJ, Meza-Arana CE, Cruz-Bautista I, Arellano-Campos O, Navarrete-López M, Aguilar-Salinas CA (2010) Daily physical activity, fasting glucose, uric acid, and body mass index are independent factors associated with serum fibroblast growth factor 21 levels. Eur J Endocrinol 163:469–477PubMed

Cyphert HA, Alonge KM, Ippagunta SM, Hillgartner FB (2014) Glucagon stimulates hepatic FGF21 secretion through a PKA-and EPAC-dependent posttranscriptional mechanism. PLoS ONE 9:e94996PubMedPubMedCentral

Dahlman I, Nilsson M, Gu HF, Lecoeur C, Efendic S, Östenson CG, Brismar K, Gustafsson J-Å, Froguel P, Vaxillaire M (2009) Functional and genetic analysis in type 2 diabetes of liver X receptor alleles–a cohort study. BMC Med Genet 10:1–13

DeFronzo RA, Buse JB, Kim T, Burns C, Skare S, Baron A, Fineman M (2016) Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials. Diabetologia 59:1645–1654PubMedPubMedCentral

Díaz-Delfín J, Hondares E, Iglesias R, Giralt M, Caelles C, Villarroya F (2012) TNF-α represses β-Klotho expression and impairs FGF21 action in adipose cells: involvement of JNK1 in the FGF21 pathway. Endocrinology 153:4238–4245PubMed

Fisher FM, Chui PC, Antonellis PJ, Bina HA, Kharitonenkov A, Flier JS, Maratos-Flier E (2010) Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 59:2781–2789PubMedPubMedCentral

Gaich G, Chien JY, Fu H, Glass LC, Deeg MA, Holland WL, Kharitonenkov A, Bumol T, Schilske HK, Moller DE (2013) The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab 18:333–340PubMed

Guo C, Zhao L, Li Y, Deng X, Yuan G (2021) Relationship between FGF21 and drug or nondrug therapy of type 2 diabetes mellitus. J Cell Physiol 236:55–67PubMed

Hale C, Chen MM, Stanislaus S, Chinookoswong N, Hager T, Wang M, Véniant MM, Xu J (2012) Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance. Endocrinology 153:69–80PubMed

Herman R, Kravos NA, Jensterle M, Janež A, Dolžan V (2022) Metformin and insulin resistance: a review of the underlying mechanisms behind changes in GLUT4-mediated glucose transport. Int J Mol Sci 23:1264PubMedPubMedCentral

Hua S, Liu Q, Li J, Fan M, Yan K, Ye D (2021) Beta-klotho in type 2 diabetes mellitus: From pathophysiology to therapeutic strategies. Rev Endocr Metab Disord 22:1091–1109PubMed

Huddar A, Govindaraj P, Chiplunkar S, Deepha S, Ponmalar JJ, Philip M, Nagappa M, Narayanappa G, Mahadevan A, Sinha S (2021) Serum fibroblast growth factor 21 and growth differentiation factor 15: two sensitive biomarkers in the diagnosis of mitochondrial disorders. Mitochondrion 60:170–177PubMed

Ikram M, Magdy Beshbishy A, Kifayatullah M, Olukanni A, Zahoor M, Naeem M, Amin M, Shah M, Abdelaziz AS, Ullah R (2020) Chemotherapeutic potential of Carthamus oxycantha root extract as antidiarrheal and in vitro antibacterial activities. Antibiotics 9:226PubMedPubMedCentral

Kappe C, Patrone C, Holst JJ, Zhang Q, Sjöholm Å (2013) Metformin protects against lipoapoptosis and enhances GLP-1 secretion from GLP-1-producing cells. J Gastroenterol 48:322–332PubMed

Kar E, Alataş Ö, Şahıntürk V, Öz S (2022) Effects of metformin on lipopolysaccharide induced inflammation by activating fibroblast growth factor 21. Biotech Histochem 97:44–52PubMed

Kaufman A, Abuqayyas L, Denney WS, Tillman EJ, Rolph T (2020) AKR-001, an Fc-FGF21 analog, showed sustained pharmacodynamic effects on insulin sensitivity and lipid metabolism in type 2 diabetes patients. Cell Rep Med 1:100057PubMedPubMedCentral

Kenechukwu FC, Nnamani DO, Momoh MA, Attama AA (2022) Enhanced circulation longevity and pharmacodynamics of metformin from surface-modified nanostructured lipid carriers based on solidified reverse micellar solutions. Heliyon 8:e09100PubMedPubMedCentral

Kim KH, Jeong YT, Kim SH, Jung HS, Park KS, Lee H-Y, Lee M-S (2013) Metformin-induced inhibition of the mitochondrial respiratory chain increases FGF21 expression via ATF4 activation. Biochem Biophys Res Commun 440:76–81PubMed

Kim KH, Lee M-S (2015) FGF21 as a mediator of adaptive responses to stress and metabolic benefits of anti-diabetic drugs. J Endocrinol 226:R1-16PubMed

Kim JH, Bae KH, Choi YK, Go Y, Choe M, Jeon YH, Lee HW, Koo SH, Perfield J, Harris R (2015) Fibroblast growth factor 21 analogue LY2405319 lowers blood glucose in streptozotocin-induced insulin-deficient diabetic mice by restoring brown adipose tissue function. Diabet Obes Metab 17:161–169

Kim EK, Lee SH, Jhun JY, Byun JK, Jeong JH, Lee SY, Kim JK, Choi JY, Cho ML (2016) Metformin prevents fatty liver and improves balance of white/brown adipose in an obesity mouse model by inducing FGF21. Mediat Inflamm 2016:1–13

Kim E-K, Lee SH, Lee S-Y, Kim J-k, Jhun JY, Na HS, Kim S-Y, Choi JY, Yang CW, Park S-H (2018) Metformin ameliorates experimental-obesity-associated autoimmune arthritis by inducing FGF21 expression and brown adipocyte differentiation. Exp Mol Med 50:e432–e432PubMedPubMedCentral

Kovatchev B, Cobelli C (2016) Glucose variability: timing, risk analysis, and relationship to hypoglycemia in diabetes. Diabetes Care 39:502–510PubMedPubMedCentral

Larson KR, Chaffin AT, Goodson ML, Fang Y, Ryan KK (2019) Fibroblast growth factor-21 controls dietary protein intake in male mice. Endocrinology 160:1069–1080PubMedPubMedCentral

Li K, Li L, Yang M, Liu H, Boden G, Yang G (2012) The effects of fibroblast growth factor-21 knockdown and over-expression on its signaling pathway and glucose–lipid metabolism in vitro. Mol Cell Endocrinol 348:21–26PubMed

Li Y, Wong K, Giles A, Jiang J, Lee JW, Adams AC, Kharitonenkov A, Yang Q, Gao B, Guarente L (2014) Hepatic SIRT1 attenuates hepatic steatosis and controls energy balance in mice by inducing fibroblast growth factor 21. Gastroenterology 146(539–549):e537

Li Q, Jia S, Xu L, Li B, Chen N (2019) Metformin-induced autophagy and irisin improves INS-1 cell function and survival in high-glucose environment via AMPK/SIRT1/PGC-1α signal pathway. Food Sci Nutr 7:1695–1703PubMedPubMedCentral

Lin M-J, Dai W, Scott MJ, Li R, Zhang Y-Q, Yang Y, Chen L-Z, Huang X-S (2017) Metformin improves nonalcoholic fatty liver disease in obese mice via down-regulation of apolipoprotein A5 as part of the AMPK/LXRα signaling pathway. Oncotarget 8:108802PubMedPubMedCentral

Liu J, Yang K, Yang J, Xiao W, Le Y, Yu F, Gu L, Lang S, Tian Q, Jin T (2019) Liver-derived fibroblast growth factor 21 mediates effects of glucagon-like peptide-1 in attenuating hepatic glucose output. EBioMedicine 41:73–84PubMedPubMedCentral

Luo F, Guo Y, Ruan G, Li X (2016) Metformin promotes cholesterol efflux in macrophages by up-regulating FGF21 expression: a novel anti-atherosclerotic mechanism. Lipids Health Dis 15:1–2

Mai K, Andres J, Biedasek K, Weicht J, Bobbert T, Sabath M, Meinus S, Reinecke F, Möhlig M, Weickert MO (2009) Free fatty acids link metabolism and regulation of the insulin-sensitizing fibroblast growth factor-21. Diabetes 58:1532–1538PubMedPubMedCentral

Maida A, Lamont B, Cao X, Drucker D (2011) Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice. Diabetologia 54:339–349PubMed

Majeed Y, Upadhyay R, Lakshmanan A, Triggle C, Ding H (2016) Down-regulation of Erk and sirt1 signaling may lead to reduced Fgf-21 sensitivity in a mouse model of diabetes. Qatar Found Annu Res Conf Proceed 2016:HBPP1804

Markowicz-Piasecka M, Sadkowska A, Huttunen KM, Podsiedlik M, Mikiciuk-Olasik E, Sikora J (2020) An investigation into the pleiotropic activity of metformin a glimpse of haemostasis. Eur J Pharmacol 872:172984PubMed

Nie F, Wu D, Du H, Yang X, Yang M, Pang X, Xu Y (2017) Serum klotho protein levels and their correlations with the progression of type 2 diabetes mellitus. J Diabet Complicat 31:594–598

Nygaard EB, Vienberg SG, Ørskov C, Hansen HS, Andersen B (2012) Metformin stimulates FGF21 expression in primary hepatocytes. Exp Diabet Res. 2012:465282

Nygaard EB, Møller CL, Kievit P, Grove KL, Andersen B (2014) Increased fibroblast growth factor 21 expression in high-fat diet-sensitive non-human primates (Macaca mulatta). Int J Obes 38:183–191

Ojha A, Ojha U, Mohammed R, Chandrashekar A, Ojha H (2019) Current perspective on the role of insulin and glucagon in the pathogenesis and treatment of type 2 diabetes mellitus. Clin Pharmacol 11:57–65PubMedPubMedCentral

Omar BA, Andersen B, Hald J, Raun K, Nishimura E, Ahrén B (2014) Fibroblast growth factor 21 (FGF21) and glucagon-like peptide 1 contribute to diabetes resistance in glucagon receptor-deficient mice. Diabetes 63:101–110PubMed

Ouyang J, Parakhia RA, Ochs RS (2011) Metformin activates AMP kinase through inhibition of AMP deaminase. J Biol Chem 286:1–11PubMed

Pérez-Martí A, Sandoval V, Marrero PF, Haro D, Relat J (2017) Nutritional regulation of fibroblast growth factor 21: from macronutrients to bioactive dietary compounds. Horm Mol Biol Clin Investig 30:20160034

Pinyopornpanish K, Leerapun A, Pinyopornpanish K, Chattipakorn N (2021) Effects of metformin on hepatic steatosis in adults with nonalcoholic fatty liver disease and diabetes: insights from the cellular to patient levels. Gut Liver 15:827PubMedPubMedCentral

Prudhomme GJ, Kurt M, Qinghua WangPrudhomme GJ, Kurt M, Wang Q (2022) Pathobiology of the klotho antiaging protein and therapeutic considerations. Front Aging. https://doi.org/10.3389/fragi.2022.931331CrossRefPubMed

Qiao YC, Chen YL, Pan YH, Ling W, Tian F, Zhang XX, Zhao HL (2017) Changes of transforming growth factor beta 1 in patients with type 2 diabetes and diabetic nephropathy: A PRISMA-compliant systematic review and meta-analysis. Medicine 96(15):e6583PubMedPubMedCentral

Rasheed HA, Al-Kuraishy HM, Al-Gareeb AI, Hussien NR, Al-Nami MS (2019) Effects of diabetic pharmacotherapy on prolactin hormone in patients with type 2 diabetes mellitus: Bane or Boon. J Adv Pharm Technol Res 10:163PubMedPubMedCentral

Reinehr T, Woelfle J, Wunsch R, Roth CL (2012) Fibroblast growth factor 21 (FGF-21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: a longitudinal analysis. J Clin Endocrinol Metab 97:2143–2150PubMed

Rena G, Hardie DG, Pearson ER (2017) The mechanisms of action of metformin. Diabetologia 60:1577–1585PubMedPubMedCentral

Rodgers M, Heineman B, Dushay J (2019) Increased fructose consumption has sex-specific effects on fibroblast growth factor 21 levels in humans. Obes Sci Pract 5:503–510PubMedPubMedCentral

Samms RJ, Lewis JE, Norton L, Stephens FB, Gaffney CJ, Butterfield T, Smith DP, Cheng CC, Perfield JW, Adams AC (2017) FGF21 is an insulin-dependent postprandial hormone in adult humans. J Clin Endocrinol Metab 102:3806–3813PubMedPubMedCentral

Slusher A, Whitehurst M, Zoeller R, Mock J, Maharaj M, Huang C-J (2015) Attenuated fibroblast growth factor 21 response to acute aerobic exercise in obese individuals. Nutr Metab Cardiovasc Dis 25:839–845PubMed

So WY, Leung PS (2016) Fibroblast growth factor 21 as an emerging therapeutic target for type 2 diabetes mellitus. Med Res Rev 36:672–704PubMed

Solomon TP, Carter S, Haus JM, Karstoft K, von Holstein-Rathlou S, Nielsen MS, Gillum MP (2022) Plasma FGF21 concentrations are regulated by glucose independently of insulin and GLP-1 in lean, healthy humans. PeerJ 10:e12755PubMedPubMedCentral

Sun H, Sherrier M, Li H (2021) Skeletal muscle and bone-emerging targets of fibroblast growth factor-21. Front Physiol. https://doi.org/10.3389/fphys.2021.625287269CrossRefPubMedPubMedCentral

Targher G, Corey KE, Byrne CD, Roden M (2021) The complex link between NAFLD and type 2 diabetes mellitus—mechanisms and treatments. Nat Rev Gastroenterol Hepatol 18:599–612PubMed

Uebanso T, Taketani Y, Yamamoto H, Amo K, Tanaka S, Arai H, Takei Y, Masuda M, Yamanaka-Okumura H, Takeda E (2012) Liver X receptor negatively regulates fibroblast growth factor 21 in the fatty liver induced by cholesterol-enriched diet. J Nutr Biochem 23:785–790PubMed

Valiño-Rivas L, Cuarental L, Ceballos MI, Pintor-Chocano A, Perez-Gomez MV, Sanz AB, Ortiz A, Sanchez-Niño MD (2022) Growth differentiation factor-15 preserves Klotho expression in acute kidney injury and kidney fibrosis. Kidney Int 101:1200–1215PubMed

Wang C, Guo F (2012) Effects of activating transcription factor 4 deficiency on carbohydrate and lipid metabolism in mammals. IUBMB Life 64:226–230PubMed

Watanabe H, Miyahisa M, Chikamatsu M, Nishida K, Minayoshi Y, Takano M, Ichimizu S, Kobashigawa Y, Morioka H, Maeda H (2020) Development of a long acting FGF21 analogue-albumin fusion protein and its anti-diabetic effects. J Control Release 324:522–531PubMed

Woo Y, Xu A, Wang Y, Lam KS (2013) Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives. Clin Endocrinol (oxf) 78:489–496PubMed

Xiao Y, Xu A, Law LS, Chen C, Li H, Li X, Yang L, Liu S, Zhou Z, Lam KS (2012) Distinct changes in serum fibroblast growth factor 21 levels in different subtypes of diabetes. J Clin Endocrinol Metab 97:E54–E58PubMed

Xue J, Wang L, Sun Z, Xing C (2019) Basic research in diabetic nephropathy health care: a study of the renoprotective mechanism of metformin. J Med Syst 43:1–13

Ye X, Qi J, Yu D, Wu Y, Zhu S, Li S, Wu Q, Ren G, Li D (2017) Pharmacological efficacy of FGF21 analogue, liraglutide and insulin glargine in treatment of type 2 diabetes. J Diabet Complicat 31:726–734

Yu J, Yu B, Jiang H, Chen D (2012) Conjugated linoleic acid induces hepatic expression of fibroblast growth factor 21 through PPAR-α. Br J Nutr 107:461–465PubMed

Yu Y, He J, Li S, Song L, Guo X, Yao W, Zou D, Gao X, Liu Y, Bai F (2016) Fibroblast growth factor 21 (FGF21) inhibits macrophage-mediated inflammation by activating Nrf2 and suppressing the NF-κB signaling pathway. Int Immunopharmacol 38:144–152PubMed

Zhang L, Liu T (2018) Clinical implication of alterations in serum Klotho levels in patients with type 2 diabetes mellitus and its associated complications. J Diabet Complicat 32:922–930

Zhang J, Weng W, Wang K, Lu X, Cai L, Sun J (2018a) The role of FGF21 in type 1 diabetes and its complications. Int J Biol Sci 14:1000PubMedPubMedCentral

Zhang M, Sun W, Qian J, Tang Y (2018b) Fasting exacerbates hepatic growth differentiation factor 15 to promote fatty acid β-oxidation and ketogenesis via activating XBP1 signaling in liver. Redox Biol 16:87–96PubMedPubMedCentral

Zhang D, Ma Y, Liu J, Deng Y, Zhou B, Wen Y, Li M, Wen D, Ying Y, Luo S (2021) Metformin alleviates hepatic steatosis and insulin resistance in a mouse model of high-fat diet-induced nonalcoholic fatty liver disease by promoting transcription factor EB-dependent autophagy. Front Pharmacol 12:689111PubMedPubMedCentral

Zhou M, Xia L, Wang J (2007) Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine. Drug Metab Disposition 35:1956–1962

Zibar K, Blaslov K, Bulum T, Ćuća JK, Smirčić-Duvnjak L (2015) Basal and postprandial change in serum fibroblast growth factor-21 concentration in type 1 diabetic mellitus and in healthy controls. Endocrine 48:848–855PubMed

Title: The potential effect of metformin on fibroblast growth factor 21 in type 2 diabetes mellitus (T2DM)
Authors: Hayder M. Al-kuraishy
Ali I. Al-Gareeb
Hebatallah M. Saad
Gaber El-Saber Batiha
Publication date: 19-06-2023
Publisher: Springer International Publishing
Keywords: Metformin
Insulins
Insulins
Diabetes
Type 2 Diabetes
Published in: Inflammopharmacology / Issue 4/2023
Print ISSN: 0925-4692
Electronic ISSN: 1568-5608
DOI: https://doi.org/10.1007/s10787-023-01255-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The potential effect of metformin on fibroblast growth factor 21 in type 2 diabetes mellitus (T2DM)

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2023

Diosgenin, a steroidal sapogenin, arrests arthritis through modulation of inflammatory cytokines and oxidative stress biomarkers in Wistar rats

Inhibition of STAT3 phosphorylation by colchicine regulates NLRP3 activation to alleviate sepsis-induced acute lung injury

Beneficial effects of flavonoids on cardiovascular diseases by influencing NLRP3 inflammasome

Anti-arthritic effects of geranium essential oil loaded chitosan nanoparticles in Freund’s complete adjuvant induced arthritic rats through down-regulation of inflammatory cytokines

Ischemic tubular injury: Oxygen-sensitive signals and metabolic reprogramming

Fractionated whole body γ-irradiation aggravates arthritic severity via boosting NLRP3 and RANKL expression in adjuvant-induced arthritis model: the mitigative potential of ebselen